<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00095862</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000393552</org_study_id>
    <secondary_id>WRI-GEV-007</secondary_id>
    <nct_id>NCT00095862</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers</brief_title>
  <official_title>A Phase 1-2 Study for Stage IV Breast and HER2/Neu Positive Cancers to Evaluate the Safety and Efficacy of a Vaccine Using Whole Cells From the SVBR- 1-GM Cell Line Genetically Engineered To Produce Granulocyte- Macrophage Colony Stimulating Factor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wiseman Research Initiatives LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from gene-modified tumor cells may make the body build an immune&#xD;
      response to kill tumor cells. Drugs used in chemotherapy, such as cyclophosphamide, work in&#xD;
      different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa&#xD;
      may interfere with the growth of tumor cells. Combining vaccine therapy with cyclophosphamide&#xD;
      and interferon alfa may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combining vaccine therapy with&#xD;
      interferon alfa and cyclophosphamide in treating patients who have stage IV breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety, tolerability, and feasibility of vaccine therapy comprising an&#xD;
           allogeneic (non-self) tumor cell line transfected with the sargramostim (GM-CSF) gene&#xD;
           combined with low-dose interferon alfa and low-dose cyclophosphamide in patients with&#xD;
           stage IV breast cancer or other solid tumors.&#xD;
&#xD;
        -  Determine the clinical response, time to progression, and survival of patients treated&#xD;
           with this regimen.&#xD;
&#xD;
        -  Correlate clinical response with immunological response in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
      OUTLINE: Patients receive low-dose cyclophosphamide IV once 2-3 days before each tumor&#xD;
      vaccine. Patients then receive tumor vaccine comprising HER2/neu-positive allogeneic&#xD;
      (non-self) breast cancer cells transfected with the sargramostim (GM-CSF) gene intradermally&#xD;
      (ID) on day 1. Patients also receive low-dose interferon alfa ID approximately 48 and 96&#xD;
      hours after each tumor vaccine. Treatment repeats every 2 weeks for 3 vaccinations and then&#xD;
      monthly for 3 vaccinations in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed at 2 weeks and then every 3 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 9-24 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>November 2004</start_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety, tolerability, and feasibility</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical response</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to progression</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of clinical response with immunological response</measure>
  </primary_outcome>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>allogeneic GM-CSF-secreting breast cancer vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alfa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed breast cancer meeting 1 of the following criteria:&#xD;
&#xD;
               -  Recurrent and/or metastatic lesions that are HER2/neu-positive or negative&#xD;
&#xD;
               -  Recurrent or progressive cancer of the lung, ovary, pancreas, prostate, bladder,&#xD;
                  or other primary site associated with HER2/neu-positive tumor by histochemistry&#xD;
&#xD;
          -  Bone-only metastatic breast cancer, cytologically confirmed malignant effusions,&#xD;
             histologically confirmed marrow involvement, or other evaluable (but non-measurable)&#xD;
             metastatic disease allowed&#xD;
&#xD;
          -  Failed prior first-line chemotherapy (e.g., anthracycline- or taxane-based therapy)&#xD;
             with or without adjuvant chemotherapy or hormonal therapy&#xD;
&#xD;
          -  No curative or reliably effective palliative surgery, radiotherapy, or medical therapy&#xD;
             available&#xD;
&#xD;
          -  Stable brain metastases allowed provided the following criteria are met*:&#xD;
&#xD;
               -  Previously treated&#xD;
&#xD;
               -  No concurrent requirement for corticosteroids&#xD;
&#xD;
               -  No radiological or clinical deterioration within the past 6 weeks NOTE: *Patients&#xD;
                  who had recent treatment with gamma knife or intensity-modulated radiotherapy for&#xD;
                  brain metastases are eligible provided there has been recovery from known or&#xD;
                  anticipated toxic effects&#xD;
&#xD;
          -  Patients with no HLA-A2 allele are eligible&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female or male&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 4 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute granulocyte count ≥ 1,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 2 mg/dL&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT and AST ≤ 2 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  BUN ≤ 30 mg/dL&#xD;
&#xD;
          -  Creatinine ≤ 2 mg/dL&#xD;
&#xD;
          -  ≤ 1 g protein on 24-hour urine collection OR&#xD;
&#xD;
          -  ≤ 1+ proteinuria on urinalysis&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Hypertension controlled by agents (except beta-blockers) allowed&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No history of anaphylactic reaction to any known or unknown antigen&#xD;
&#xD;
          -  No history of clinical hypersensitivity to sargramostim (GM-CSF), interferon, yeast,&#xD;
             beef, or to any components used in preparation of study vaccine&#xD;
&#xD;
          -  No clinical or laboratory features indicative of AIDS&#xD;
&#xD;
          -  No rheumatological, psychiatric, or other clinically progressive major medical&#xD;
             problems requiring treatment&#xD;
&#xD;
          -  No other malignancy within the past 2 years&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 3 weeks since prior biological therapy, including trastuzumab (Herceptin^®)&#xD;
&#xD;
          -  More than 3 weeks since prior immunotherapy&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 3 weeks since prior chemotherapy (8 weeks for nitrosoureas or mitomycin)&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 3 weeks since prior hormonal therapy&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
          -  No concurrent systemic steroids&#xD;
&#xD;
               -  Concurrent inhalation steroids for respiratory hypersensitivity (e.g.,&#xD;
                  triamcinolone nasal or pulmonary inhalers) allowed&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 3 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 3 weeks since prior major surgery with general anesthesia&#xD;
&#xD;
          -  No concurrent major surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  Patients receiving pamidronate, bisphosphonates, or other supportive measures must&#xD;
             continue therapy during study participation&#xD;
&#xD;
          -  No concurrent anticoagulants&#xD;
&#xD;
          -  No concurrent beta-blockers for control of mild hypertension or other indications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles L. Wiseman, MD, FACP</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Glendale Memorial Hospital Comprehensive Cancer Center</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hollywood Presbyterian Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027-0902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <study_first_submitted>November 9, 2004</study_first_submitted>
  <study_first_submitted_qc>November 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2004</study_first_posted>
  <last_update_submitted>February 1, 2018</last_update_submitted>
  <last_update_submitted_qc>February 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <name_title>Charles L. Wiseman</name_title>
    <organization>Wiseman Research Initiatives, LLC</organization>
  </responsible_party>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>male breast cancer</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

